JP2021050289A - 皮膚常在細菌lps及びその配合物 - Google Patents
皮膚常在細菌lps及びその配合物 Download PDFInfo
- Publication number
- JP2021050289A JP2021050289A JP2019174811A JP2019174811A JP2021050289A JP 2021050289 A JP2021050289 A JP 2021050289A JP 2019174811 A JP2019174811 A JP 2019174811A JP 2019174811 A JP2019174811 A JP 2019174811A JP 2021050289 A JP2021050289 A JP 2021050289A
- Authority
- JP
- Japan
- Prior art keywords
- lps
- skin
- roseomonas
- bacterium
- gram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 47
- 150000001875 compounds Chemical class 0.000 title 1
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 239000002537 cosmetic Substances 0.000 claims abstract description 9
- 241000572738 Roseomonas Species 0.000 claims description 37
- 239000000284 extract Substances 0.000 claims description 25
- 239000000843 powder Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 238000003287 bathing Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003337 fertilizer Substances 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 3
- 239000000273 veterinary drug Substances 0.000 claims description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 105
- 239000002158 endotoxin Substances 0.000 description 104
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 210000002540 macrophage Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 241000520272 Pantoea Species 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 6
- 241000606125 Bacteroides Species 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 241001227620 Roseomonas mucosa Species 0.000 description 4
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 4
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000015788 innate immune response Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 244000005714 skin microbiome Species 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 241000239218 Limulus Species 0.000 description 3
- 241000588912 Pantoea agglomerans Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 2
- 244000141359 Malus pumila Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 241000605862 Porphyromonas gingivalis Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 235000021016 apples Nutrition 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 241001529572 Chaceon affinis Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 239000012480 LAL reagent Substances 0.000 description 1
- 102000005482 Lipopolysaccharide Receptors Human genes 0.000 description 1
- 108010031801 Lipopolysaccharide Receptors Proteins 0.000 description 1
- 241001403850 Roseomonas gilardii Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008956 bacterial persistence Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical group 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Fertilizers (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
前記グラム陰性菌は、ロゼオモナス属菌であることが望ましい。
前記ロゼオモナス属菌は、ロゼオモナス・ムコザであることがさらに望ましい。
本発明のエキスは、前記皮膚常在細菌LPSを含むことを特徴とする。
本発明のエキス末は、前記皮膚常在細菌LPSを含むことを特徴とする。
8名の健常人の皮膚を生理食塩水で湿らせた綿棒でこすり、この綿棒を2mlのR2A培地(300μg/mlのバンコマイシン、5μg/mlのアンホテリシンBを含む)に浸して撹拌後、32℃で2日間培養した。この操作によりグラム陽性菌と真菌の増殖を抑え、グラム陰性菌を選択的に増殖させた。
2日間培養後、培養液から100μLを分取して寒天培地に塗布した。菌溶液を塗布した寒天培地を、37℃で1日培養した。
実施例1で選択した増殖性の高かった4菌株についてLPSの抽出を試みた。4菌株のコロニーを滅菌済みLB培地100mLの入った培養用フラスコに入れ、37℃にて1日振盪培養した。培養後、遠心チューブに培養液を移し、3500回転/分(rpm)で遠心分離を行い、ロゼオモナス菌体を回収した。湿菌体重量100mgに対し1mlの蒸留水を加え懸濁し、90℃で20分間、オートクレーブで加熱処理を行った。加熱後、ボルテックスミキサーで攪拌し、37℃で10分間超音波処理を行った。その後、3500rpmで遠心分離を行い、上清のリムラス活性を測定した。
結果を表1に示した。上記の熱水抽出法にて、湿菌体重量1gあたり約2mgから4mgのLPSが抽出されることがわかった。
実施例1で選択した4菌株をLB液体培地に植菌してから、37℃で培養した。培養後、2.0mlの培養液を遠心分離し、沈殿を回収。沈殿物にTAE(0.04M:Tris・acetate、0.001M:EDTA)とアルカリ溶液を添加し、60℃で70分処理した。熱処理後、フェノールクロロホルム溶液を加えてから、再度60℃で15分処理し、遠心分離してから、上清を回収し、プロテイナーゼKを加えて60℃で60分処理した。その後、水、酢酸ナトリウム、エタノールを加え、遠心分離後、沈殿を回収し、水を加えてLPS簡易精製サンプルを調製した。抽出及び簡易精製したLPSを電気泳動で確認した。
実施例3の後選択したロゼオモナス菌2株を菌株(1)、(2)として、2菌株のシングルコロニーをそれぞれ1mLの食塩水に懸濁し、滅菌済みLB培地100mLの入った培養用フラスコ5本に200μLずつ植菌し、37度にて2日間振盪培養した。培養後、同菌株の5本の培養液を1本の遠心チューブにまとめ、3500rpmで遠心分離を行い上清の除去を行った。菌体からのLPSの精製はWestphalらの方法に従って行った。すなわち、湿菌体重量100mgに対し1mLとなるように蒸留水を加えた。菌を懸濁してこの液に同容量の90%フェノールを加え、65℃から70℃で20分間攪拌した。その後、4℃まで液を冷却し、3500rpmで遠心分離を行った。上層の水層を別の容器に回収し、残りのフェノール層と中間層に、回収した水層と同量の蒸留水を加え、再度65℃から70℃で10分間攪拌しLPSを再抽出した。その後、4℃まで液を冷却し、遠心分離を行った。2回目の水層を一回目の水層と合わせ蒸留水で透析しフェノールを除去した。この透析内液をDNA分解酵素(ベンゾナーゼ)(50ng/ml)とタンパク分解酵素(プロティナーゼK)(100μg/ml)で処理し、フェノール抽出を行い、回収した水層をアミコンウルトラ15(ミリポア)を用いて限外ろ過により濃縮し凍結乾燥を行った。この凍結乾燥品をロゼオモナス菌の精製LPSとした。
LPSはマクロファージ細胞に働きかけることで、体の免疫力を活性化する。そこで、ロゼオモナス菌LPSについて、一酸化窒素(NO)産生量を指標として、マクロファージ細胞の活性化能を評価した。
実施例4で使用したロゼオモナス菌2株について、16SリボゾーマルDNA解析を行ったところ、菌株(1)及び菌株(2)の配列はロゼオモナス・ムコザMDA5527株の配列と相同率が100%であった。すなわち、菌株(1)、(2)ともにロゼオモナス・ムコザ(Roseomonas mucosa)であると同定された。ロゼオモナス・ムコザMDA5527株は、2003年に初めて血液から単離され、コロニーに顕著に粘液性があるためムコザと命名された菌である(非特許文献9)。
実施例6でロゼオモナス・ムコザと同定された2菌株のうち、菌株(1)を使い、エキス末の調整を行った。
Claims (6)
- 健常者皮膚に常在するグラム陰性菌から得られることを特徴とする皮膚常在細菌LPS。
- 前記グラム陰性菌が、ロゼオモナス属菌であることを特徴とする請求項1記載の皮膚常在細菌LPS。
- 前記ロゼオモナス属菌が、ロゼオモナス・ムコザであることを特徴とする請求項2記載の皮膚常在細菌LPS。
- 請求項1乃至3いずれかに記載の皮膚常在細菌LPSを含むことを特徴とするエキス。
- 請求項1乃至3いずれかに記載の皮膚常在細菌LPSを含むことを特徴とするエキス末。
- 請求項1乃至3いずれかに記載の皮膚常在細菌LPS、請求項4記載のエキス又は請求項記載5記載のエキス末が配合されている医薬品、動物用医薬品、動物用食品、動物用スキンケア製品、動物用雑貨、医薬部外品、化粧品、食品、機能性食品、飼料、日用品雑貨、植物用薬品、植物用肥料又は浴用剤であることを特徴とするLPS配合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019174811A JP2021050289A (ja) | 2019-09-26 | 2019-09-26 | 皮膚常在細菌lps及びその配合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019174811A JP2021050289A (ja) | 2019-09-26 | 2019-09-26 | 皮膚常在細菌lps及びその配合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021050289A true JP2021050289A (ja) | 2021-04-01 |
Family
ID=75157065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019174811A Pending JP2021050289A (ja) | 2019-09-26 | 2019-09-26 | 皮膚常在細菌lps及びその配合物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2021050289A (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7180941B1 (ja) | 2021-08-02 | 2022-11-30 | 株式会社創研 | 皮脂分泌抑制剤 |
CN116617269A (zh) * | 2023-05-17 | 2023-08-22 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 粘液玫瑰单胞菌活菌制剂及胞外多糖在制备用于缓解uvb导致的皮肤损伤的药物中的应用 |
-
2019
- 2019-09-26 JP JP2019174811A patent/JP2021050289A/ja active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7180941B1 (ja) | 2021-08-02 | 2022-11-30 | 株式会社創研 | 皮脂分泌抑制剤 |
JP2023021927A (ja) * | 2021-08-02 | 2023-02-14 | 株式会社創研 | 皮脂分泌抑制剤 |
CN116617269A (zh) * | 2023-05-17 | 2023-08-22 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 粘液玫瑰单胞菌活菌制剂及胞外多糖在制备用于缓解uvb导致的皮肤损伤的药物中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101761578B1 (ko) | 신규한 장병원성 대장균 박테리오파지 Esc-CHP-2 및 이의 장병원성 대장균 증식 억제 용도 | |
KR101381797B1 (ko) | 신규 박테리오파지 및 이를 포함하는 항균 조성물 | |
TWI459951B (zh) | 新穎噬菌體及含該噬菌體之抗菌組成物 | |
EP3133152B1 (en) | Novel bacteriophage, and composition containing same | |
EA018687B1 (ru) | Фракция гликолипидов ферментированных экстрактов биологического пищевого материала и фармацевтическая композиция, содержащая указанную фракцию | |
CN106232805B (zh) | 新型噬菌体以及包含其的组合物 | |
CN105308179B (zh) | 噬菌体、包括其的组成物及其应用 | |
Acurcio et al. | Milk fermented by Lactobacillus species from Brazilian artisanal cheese protect germ-free-mice against Salmonella Typhimurium infection | |
JP6833418B2 (ja) | リポ多糖、リポ多糖製造方法及びリポ多糖配合物 | |
JP2021050289A (ja) | 皮膚常在細菌lps及びその配合物 | |
KR20150118837A (ko) | 신규 박테리오파지 및 이를 포함하는 조성물 | |
Umpiérrez et al. | Innate immune responses to Proteus mirabilis flagellin in the urinary tract | |
Ghalem | Antioxidant and antimicrobial activities of exopolysaccharides from yoghurt starter | |
JP3017493B1 (ja) | 自己免疫疾患予防組成物 | |
Ishijima et al. | Protection of mice from oral candidiasis by heat-killed enterococcus faecalis, possibly through its direct binding to Candida albicans | |
Venkatalakshmi et al. | Immunostimulatory effect of Lactobacillus sporogenes on the nonspecific defense mechanisms of Oreochromis mossambicus (Peters) | |
EP3135761B1 (en) | Novel bacteriophage and composition comprising same | |
JPH0899887A (ja) | 免疫賦活剤 | |
KR101434741B1 (ko) | 페실로마이세스 바리오티 바라이어티 브른네오러스 gpp1101b 균주 및 이를 이용한 제제 | |
Zhang et al. | Low-molecular-weight chitosan relieves enterotoxigenic Escherichia coli-induced growth retardation in weaned pigs | |
Schmidt et al. | Isolation of Bartonella quintana from an HIV-positive patient with bacillary angiomatosis | |
JP3649787B2 (ja) | 魚類の腸球菌感染症用予防剤およびその用途 | |
María et al. | Biopolymer production by bacteria isolated from native stingless bee honey, Scaptotrigona jujuyensis | |
KR102037398B1 (ko) | 신규한 살모넬라균 특이 박테리오파지 sg102 및 이를 포함하는 항균 조성물 | |
KR101842668B1 (ko) | 신규한 살모넬라균 특이 박테리오파지 sg2 및 이를 포함하는 항균 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220808 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230712 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230911 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231101 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240131 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240311 |